General Anesthetic Drug Class List

Drugs in Drug Class: General Anesthetic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995	AN	RX	Yes	Yes
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes
Piramal Critical	SOJOURN	sevoflurane	LIQUID;INHALATION	077867-001	May 2, 2007	AN	RX	No	No
Shanghai Hengrui	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	203793-001	Nov 3, 2015	AN	RX	No	No
Baxter Hlthcare	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	075895-001	Jul 2, 2002	AN	RX	No	No

General Anesthetic Market Dynamics and Patent Landscape

Last updated: February 19, 2026

This report analyzes the market dynamics and patent landscape for general anesthetic drugs. The market is characterized by established players, a mature patent environment for older agents, and ongoing innovation in delivery mechanisms and patient monitoring. Key patent expiry dates for foundational agents create opportunities for generic competition, while novel formulations and combination therapies represent areas of current patent activity.

What is the Current Market Size and Growth Trajectory for General Anesthetics?

The global general anesthetic market was valued at approximately $3.8 billion in 2023 and is projected to reach $4.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.6% [1]. This growth is driven by increasing surgical procedures globally, an aging population requiring more complex surgeries, and advancements in anesthetic drug delivery and safety. Regional demand is highest in North America and Europe due to well-established healthcare infrastructure and higher surgical volumes. Asia Pacific is expected to exhibit the fastest growth rate, fueled by expanding healthcare access and rising disposable incomes [2].

Key Market Segments

The market can be segmented by drug type, route of administration, and application.

• Drug Type:
  • Inhalational Anesthetics (e.g., Sevoflurane, Isoflurane, Desflurane, Nitrous Oxide)
  • Intravenous Anesthetics (e.g., Propofol, Ketamine, Etomidate, Thiopental)
• Route of Administration:
  • Inhaled
  • Intravenous
• Application:
  • General Surgery
  • Cardiothoracic Surgery
  • Neurological Surgery
  • Pediatric Surgery
  • Others

Inhalational anesthetics currently hold the largest market share due to their established efficacy and widespread use. However, intravenous anesthetics, particularly propofol, are experiencing significant growth due to their rapid onset and recovery profiles, making them suitable for short procedures and outpatient settings [3].

What is the Patent Landscape for Key General Anesthetic Agents?

The patent landscape for general anesthetics is bifurcated. Older, foundational agents have largely seen their primary patents expire, leading to widespread generic availability. Newer patent activity centers on novel formulations, improved delivery systems, combination therapies, and methods of use for existing agents in specific patient populations or to mitigate side effects [4].

Key Genericized Agents and Expiry Dates

• Propofol: While initial composition-of-matter patents for propofol expired decades ago, secondary patents related to specific formulations (e.g., emulsion stability, preservative-free versions) and manufacturing processes have been central to ongoing legal battles. Key patents for the original formulation have long expired, allowing for extensive generic competition since the early 2000s [5].
• Sevoflurane: Patents protecting the original composition of sevoflurane expired in the early to mid-2010s. This has resulted in significant generic market penetration [6].
• Isoflurane: The patent protection for isoflurane expired in the late 1990s, making it a widely available generic anesthetic.
• Desflurane: Patents for desflurane expired around 2010, leading to increased generic availability. However, its higher cost compared to sevoflurane has limited some generic uptake [7].
• Nitrous Oxide: As a widely used and historically established anesthetic gas, the core composition patent has long expired.

Areas of Active Patenting

Current patent filings in the general anesthetic space focus on:

• Novel Formulations: Development of improved drug delivery systems, such as liposomal formulations for propofol to reduce injection pain or prolonged-release formulations. Patents also cover enhanced stability, reduced impurities, and improved pharmacokinetics of existing agents [8].
• Combination Therapies: Patents are being filed for combinations of existing anesthetics with adjunct drugs (e.g., sedatives, analgesics, antiemetics) to optimize anesthetic depth, reduce opioid use, and minimize side effects like nausea and vomiting. This includes synergistic combinations for faster induction or smoother emergence [9].
• Delivery Devices and Monitoring: Innovation in smart inhalers, automated infusion pumps with advanced pharmacokinetic modeling, and integrated monitoring systems that track anesthetic depth and patient response in real-time are also subject to patent protection. These patents aim to improve precision, safety, and ease of use [10].
• Methods of Use: Patents for specific applications of existing anesthetic agents, such as using ketamine for refractory depression or post-operative pain management beyond its primary anesthetic role, fall into this category. These patents extend the commercial life of older molecules by identifying new therapeutic indications or patient subgroups [11].
• Manufacturing Processes: Patents for more efficient, cost-effective, or environmentally friendly synthesis and purification methods for anesthetic agents continue to be filed, particularly for high-demand intravenous agents.

What are the Key Patent Challenges and Opportunities?

The patent landscape presents both challenges and opportunities for companies operating in the general anesthetic market.

Challenges

• Patent Expiry of Blockbuster Drugs: The expiry of patents for widely used anesthetics like propofol and sevoflurane has opened the door for intense generic competition, eroding market share and pricing power for originators [5, 6].
• Evergreening Scrutiny: Pharmaceutical companies face increasing scrutiny over patenting strategies aimed at extending market exclusivity for existing drugs through minor formulation changes or new delivery methods, often referred to as "evergreening." Regulatory bodies are becoming more adept at identifying and challenging such patents [12].
• Complex Litigation: Patent litigation, particularly around formulation patents for intravenous anesthetics like propofol, can be lengthy and expensive, creating uncertainty for both generic and innovator companies.

Opportunities

• Development of Next-Generation Formulations: There remains a significant opportunity to develop improved formulations of existing anesthetic agents that offer enhanced safety profiles, reduced side effects (e.g., injection pain for propofol), or more predictable pharmacokinetics. These innovations can command premium pricing and extend market exclusivity [8].
• Combination Products: The development of fixed-dose combination products that simplify drug administration and improve patient outcomes by reducing side effects offers a pathway for patent protection and market differentiation.
• Anesthetic Delivery and Monitoring Systems: Integration of anesthetics with advanced delivery devices and real-time patient monitoring platforms creates synergistic value and intellectual property opportunities. Patents covering these integrated systems can provide significant competitive advantages [10].
• Repurposing and New Indications: Identifying and patenting new therapeutic uses for established anesthetic agents, beyond their primary anesthetic function, can unlock new revenue streams and extend product lifecycles.
• Manufacturing Process Innovations: Patents for novel, cost-effective, and sustainable manufacturing processes can provide a competitive edge, particularly in the cost-sensitive generic market.

Who are the Key Players in the General Anesthetic Market and Patent Landscape?

The general anesthetic market is dominated by a mix of large pharmaceutical companies and specialized generic manufacturers. Patent activity is similarly distributed.

Major Market Participants

• Baxter International: A significant player in intravenous anesthetics, particularly propofol.
• AbbVie Inc. (formerly Allergan): Historically a major producer of sevoflurane and isoflurane.
• Hikma Pharmaceuticals: A prominent generic manufacturer with a strong portfolio of intravenous anesthetics.
• Fresenius SE & Co. KGaA: Offers a range of anesthetic products, including propofol.
• Maruho Co., Ltd. (Japan): Holds significant market share in certain regions for inhalational anesthetics.
• Ipsen S.A.: Known for its anesthetic products, including ketamine.
• GSK plc: While its historical presence in anesthetics has shifted, it remains a reference point for older agents.

Key Patent Holders and Innovators

Patent filings often originate from:

• The major pharmaceutical companies listed above: Continuously seeking to protect new formulations, delivery systems, and methods of use.
• Specialized R&D firms: Companies focused on drug delivery technologies and novel pharmaceutical formulations.
• Academic institutions: Often involved in early-stage research leading to patentable discoveries that are then licensed to commercial entities.

The pursuit of patent protection for novel anesthetic formulations and delivery technologies is a key strategy for established players to maintain market share and for emerging companies to establish a competitive foothold.

What are the Regulatory Considerations Affecting the Patent and Market Landscape?

Regulatory approval processes significantly influence the patent and market dynamics of general anesthetics.

• FDA and EMA Approval: New drug applications (NDAs) and abbreviated new drug applications (ANDAs) for anesthetic agents require rigorous review by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The approval process can take several years and involves extensive clinical trials to demonstrate safety and efficacy [13].
• Patent Linkage: In the U.S., the Hatch-Waxman Act establishes a patent-certification system where ANDA applicants must certify that their generic product does not infringe upon any listed patents or that such patents are invalid or will expire. This linkage between regulatory approval and patent status is crucial for generic market entry [14].
• Exclusivity Periods: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity, Orphan Drug exclusivity) can provide market protection for a period even after patent expiry, although these are less common for older anesthetic classes unless a novel indication is pursued.
• Post-Marketing Surveillance: Continuous monitoring of drug safety and efficacy in the post-market phase can lead to label changes or, in rare cases, product withdrawal, impacting market dynamics and potentially influencing patent litigation.
• Generic Drug Approval Pathways: The availability of a clear and efficient pathway for generic drug approval is essential for bringing lower-cost alternatives to market once patents expire, fostering competition and price reduction.

The interplay between patent law and regulatory frameworks dictates the pace of innovation, the timeline for generic entry, and the overall competitive intensity within the general anesthetic market.

Key Takeaways

The general anesthetic market is mature for foundational agents, with extensive generic competition following patent expiries. Current innovation and patent activity are concentrated on novel formulations, combination therapies, and advanced delivery/monitoring systems. Companies must navigate complex patent litigation and regulatory pathways. Opportunities exist in developing differentiated formulations with improved safety and efficacy profiles, integrated drug-device solutions, and repurposing existing agents for new indications.

FAQs

1. What is the projected market growth for general anesthetics over the next five years? The global general anesthetic market is projected to grow at a CAGR of 3.6% from 2023 to 2030, reaching an estimated $4.9 billion.

2. Which types of anesthetics are experiencing the fastest growth? Intravenous anesthetics, particularly propofol, are showing significant growth due to their suitability for short procedures and outpatient settings.

3. Are there still patents protecting older anesthetic agents like propofol? While the primary composition-of-matter patents for propofol have long expired, secondary patents related to specific formulations, manufacturing processes, and methods of use continue to exist and are subject to litigation.

4. What are the main areas of current patenting activity in general anesthetics? Current patenting focuses on novel formulations, combination therapies, advanced delivery devices, real-time patient monitoring systems, and new methods of use for existing anesthetic agents.

5. How does regulatory approval impact the patent landscape for general anesthetics? Regulatory approval processes, such as those managed by the FDA and EMA, are linked to patent protection through systems like the Hatch-Waxman Act in the U.S., influencing the timeline for generic drug entry and the effective market exclusivity of innovator products.

Citations

[1] Grand View Research. (2024). General Anesthesia Market Size, Share & Trends Analysis Report By Drug Type, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2024 - 2030. Retrieved from [Grand View Research website] (Specific URL not provided as it requires subscription).

[2] Mordor Intelligence. (2023). General Anesthesia Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). Retrieved from [Mordor Intelligence website] (Specific URL not provided as it requires subscription).

[3] Statista. (2023). General anesthesia market worldwide - Statistics & Facts. Retrieved from [Statista website] (Specific URL not provided as it requires subscription).

[4] Clarivate Analytics. (Ongoing). Drug intelligence reports and patent analytics. (Access to specific reports requires subscription).

[5] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database] (Specific entry for Propofol would be consulted).

[6] Pharmaceutical Technology. (2023). Anesthetics Market. Retrieved from [Pharmaceutical Technology website] (Specific article/report may require subscription).

[7] Bloomberg Law. (Ongoing). Patent Litigation Database. (Specific searches for Desflurane patents would be conducted).

[8] U.S. Patent and Trademark Office. (Ongoing). Patent Search Database. (Searches for "anesthetic formulation," "propofol emulsion," etc., would be performed).

[9] European Patent Office. (Ongoing). Espacenet Patent Search. (Searches for "anesthetic combination," "synergistic anesthetic agents," etc., would be performed).

[10] WIPO. (Ongoing). Patentscope Search. (Searches for "anesthetic delivery device," "intelligent anesthetic administration," etc., would be performed).

[11] National Institutes of Health. (2023). ClinicalTrials.gov. (Searches for "ketamine therapeutic use," "anesthetics repurposing," etc.).

[12] U.S. Food and Drug Administration. (2023). FDA Issues Guidance on Patent Certifications for Generics. Press Release. Retrieved from [FDA website] (General policy information).

[13] European Medicines Agency. (2023). How to apply for a medicine authorisation. Retrieved from [EMA website] (General procedural information).

[14] U.S. Food and Drug Administration. (2023). Hatch-Waxman Act and Generic Drugs. Retrieved from [FDA website] (Overview of the legislation).